Ambiq Micro SEC Filings

Ambiq Micro, Inc. expanded its Board of Directors from six to seven members and appointed Dr. Bernard B. Banks to fill the new seat, effective January 5, 2026. He will serve as a Class III director until the company’s 2028 annual meeting of stockholders, when he is expected to stand for election.

Dr. Banks is Director of Rice University’s Doerr Institute for New Leaders and previously served on the senior leadership team and faculty at Northwestern University’s Kellogg School of Management for six years. He is a retired U.S. Army Brigadier General with experience leading organizations from 10 to over 3,000 people and holds a Ph.D. in social-organizational psychology from Columbia University along with multiple graduate degrees from leading institutions.

He will receive compensation under Ambiq Micro’s Non-Employee Director Compensation Policy and has entered into the company’s standard director indemnification agreement.

Ambiq Micro, Inc. reported that its General Counsel, Michele Kim Connors, received equity awards in the form of restricted stock units tied to the company’s common stock. On January 5, 2026, she was granted 23,759 units and a separate grant of 5,483 units, both reported as acquisitions at a price of $0 per share. After these grants, she beneficially owned 29,242 shares of common stock.

The first grant vests over time, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal quarterly installments, assuming continued service under the company’s 2025 Equity Incentive Plan. The second grant vests with 25% of the shares on April 1, 2026, and the remaining shares vesting in equal quarterly installments on the same service condition.

Ambiq Micro, Inc. filed an initial ownership report for its General Counsel, Michele Kim Connors, stating that she currently holds no securities of the company. The filing confirms her role as an officer, specifically General Counsel, and indicates that the report is filed by a single reporting person. The form also notes that no non-derivative or derivative securities are beneficially owned, clarifying that there are no current equity holdings or reportable transactions associated with her position.

Ambiq Micro, Inc. (AMBQ) reported Q3 2025 results with net sales of $18.165 million and a net loss of $9.002 million. Gross profit was $7.677 million, yielding a gross margin of 42.3%, up from 32.6% a year ago as the company shifted mix toward higher‑margin regions and products.

Operating expenses were $17.720 million (R&D $8.889 million; SG&A $8.831 million), and other income contributed $1.044 million. Cash and cash equivalents rose to $146.5 million as of September 30, 2025, supported by the completed IPO.

Capital and share structure updates: the company completed its IPO on July 31, 2025, issuing 4,600,000 shares and receiving $99.843 million in net cash proceeds; 12,729,240 preferred shares converted to common. A 1‑for‑28 reverse stock split occurred on July 18, 2025. Shares outstanding were 18,313,186 as of November 3, 2025.

Ambiq Micro, Inc. (AMBQ) furnished quarterly results via an Item 2.02 Form 8-K. The company issued a press release reporting financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1 and incorporated by reference.

The disclosure is expressly deemed “furnished” and not “filed,” which limits Section 18 liability and affects how it may be incorporated into other filings. Ambiq’s common stock trades on the NYSE under the symbol AMBQ.

Ambiq Micro (AMBQ): Kleiner Perkins-affiliated funds reported beneficial ownership of Ambiq Micro common stock as of 09/30/2025. Reported holdings include: KPCB XVI at 1,439,667 shares (7.9%); KPCB XVI Founders Fund at 49,282 shares (0.3%); KPCB XVI Associates at 1,488,949 shares (8.2%); Kleiner Perkins Select Fund at 575,867 shares (3.2%); Kleiner Perkins Select Founders Fund at 17,015 shares (0.1%); and Kleiner Perkins Select Associates at 592,882 shares (3.3%).

Each reporting person lists sole voting and dispositive power over its shares, with notes that managing members (XVI Associates or KP Select Associates, as applicable) may be deemed to have sole power to vote and dispose. The filing is a Schedule 13G, reflecting beneficial ownership positions rather than a sale or issuance.

Ambiq Micro, Inc. reported a Form 4 showing that Jeffrey G. Winzeler, the company's Chief Financial Officer and a director, was granted 52,667 restricted stock units (RSUs) on 10/02/2025. The RSUs have a grant price of $0, meaning they are equity awards that convert to common stock upon settlement rather than a cash purchase.

Per the award terms, 25% of the RSUs vest on 10/01/2026, with the remainder vesting in equal quarterly installments at a rate of 1/12 of the total grant thereafter, subject to continued service under the 2025 Equity Incentive Plan. Following the grant, the reporting person beneficially owns 52,667 shares subject to the award, held directly.

Hanson Scott McLean, who serves as Chief Financial Officer and a director of Ambiq Micro, Inc. (AMBQ), received a grant of $0-priced restricted stock units totaling 83,819 RSUs on 10/02/2025. Each RSU converts into one share of common stock upon settlement. After the grant, the reporting person beneficially owns 132,818 shares in total. The RSUs vest 25% on 10/01/2026 with the remainder vesting in equal quarterly installments of 1/12 thereafter, subject to continued service under the 2025 Equity Incentive Plan. The grant was reported on the Form 4 filed and signed by an attorney-in-fact on 10/06/2025.

Ambiq Micro, Inc. (AMBQ) reported an insider equity award: Sean Chihhsiang Chen, the company's President and COO, received 56,029 restricted stock units (RSUs) on 10/02/2025. Each RSU converts to one share of common stock upon settlement and was granted at a $0 per-share price, indicating a compensatory award rather than a purchase. The RSUs vest 25% on 10/01/2026, with the remaining shares vesting in equal quarterly installments of 1/12 thereafter, subject to continuous service under the 2025 Equity Incentive Plan. The Form 4 discloses 56,029 shares beneficially owned following the grant.